IVERIC bio, Inc.
ISEEDelisted Jul 11, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001410939
IVERIC bio, Inc. was delisted on Jul 11, 2023; its insiders filed their last Form 4 on Jul 13, 2023; 256 institutions reported holding it in 13F filings for Q2 2023, worth $5.33B in total; Soros Fund Management was the only superinvestor holding it.
Q1 2023 vs. Q4 2022
How the institutions holding IVERIC bio, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Of which not filed for Q1 2023 | Q1 2023 | Change |
|---|---|---|---|---|
| Holders | 225 | 3 | 223 | +1 |
| Shares | 147.0M | 222.4K | 147.2M | +424.1K (+0.3%) |
| Value | $3.15B | $4.76M | $3.58B | +$434.9M (+13.8%) |
3 institutions that held it in Q4 2022 haven't filed for Q1 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (36)
Institutions that held IVERIC bio, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
Sold out (35)
Institutions that held IVERIC bio, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
Not filed for Q1 2023 yet (3)
Institutions that held IVERIC bio, Inc. at the end of Q4 2022 and haven't filed a 13F for Q1 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Monarch Partners Asset Management LLC | 186,706 | $4.00M |
| Neo Ivy Capital Management | 17,910 | $383.0K |
| Aevitas Wealth Management, Inc. | 17,773 | $380.5K |